Related Experiment Video
Updated: May 22, 2026
07:53
Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
Peptide-based activation of alpha5 integrin for promoting osteogenesis
Olivia Fromigué1, Julia Brun, Caroline Marty
1Laboratory of Osteoblast Biology and Pathology, INSERM UMR-606, Paris 75475, France.
Journal of Cellular Biochemistry
|May 9, 2012
Summary
Pharmacological activation of alpha 5 integrin (ITGA5) using a synthetic peptide promotes osteoblast differentiation and bone formation. This approach enhances osteogenesis and protects cells from apoptosis, offering a potential therapeutic strategy for bone defects.
Area of Science:
- Biomedical Engineering
- Cell Biology
- Regenerative Medicine
Background:
- Osteoblastogenesis is crucial for bone formation but is impaired in various bone disorders.
- The alpha 5 integrin subunit (ITGA5) plays a key role in human mesenchymal cell osteoblast differentiation.
- Developing methods to promote osteoblastogenesis is a significant therapeutic challenge.
Purpose of the Study:
- To investigate the potential of pharmacologically activating ITGA5 using a synthetic peptide for promoting osteoblast differentiation and bone formation.
- To evaluate the in vitro and in vivo effects of ITGA5 activation on murine osteoblast function and bone formation.
- To assess the therapeutic applicability of ITGA5 activation for conditions with compromised osteoblastogenesis.
Main Methods:
- Utilized a synthetic cyclic peptide (GA-CRRETAWAC-GA) to activate ITGA5 in murine C3H10T1/2 mesenchymal cells.
- Assessed in vitro effects on cell signaling (FAK, ERK1/2-MAPKs), apoptosis, adhesion, replication, osteoblast marker gene expression (Runx2, type I collagen), and ECM mineralization.
- Administered the peptide in vivo to adult mouse cranial bone for 3 weeks and performed histomorphometric analysis to evaluate bone formation.
Main Results:
- Peptide-mediated ITGA5 activation generated FAK and ERK1/2-MAPK signaling.
- In vitro, ITGA5 activation protected cells from apoptosis, enhanced osteoblast marker gene expression, and increased ECM mineralization.
- In vivo, ITGA5 activation doubled bone thickness, decreasing apoptosis and increasing bone formation rate, comparable to BMP2 effects.
Conclusions:
- Pharmacological activation of ITGA5 effectively promotes de novo bone formation by enhancing osteoprogenitor cell differentiation and providing anti-apoptotic effects.
- The peptide-based ITGA5 activation strategy shows therapeutic promise for enhancing osteogenic capacity and inducing bone formation in compromised bone conditions.
- This approach could be valuable for treating disorders characterized by defective bone formation and impaired osteoblastogenesis.
Related Concept Videos
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:10Integrins
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: